2023 World Conference on Lung Cancer (Posters)-EP11.02. Efficacy and Safety of Camrelizumab plus Famitinib in Previously Treated Patients with Advanced Non Small Cell Lung Cancer

EP11.02. Efficacy and Safety of Camrelizumab plus Famitinib in Previously Treated Patients with Advanced Non Small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to evaluate the efficacy and safety of the combination of camrelizumab and famitinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). The study included patients who had received at least one epidermal growth factor receptor (EGFR) targeted therapy and no more than two lines of chemotherapy. The primary endpoint of the study was objective response rate (ORR), and the secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs).<br /><br />The baseline characteristics of the 23 patients included in the study showed that the majority of patients were male, had adenocarcinoma histology, and were at stage IV of the disease. The patients had previously received chemotherapy and some had also received EGFR targeted therapy and immune checkpoint inhibitor therapy.<br /><br />The study results showed that the combination therapy of camrelizumab and famitinib had promising clinical activity with a manageable safety profile. The unconfirmed ORR was 39.1% and the confirmed ORR was 30.4%. The DCR was 95.7% and the median PFS was 6.9 months. The most common adverse events were proteinuria, hypercholesterolemia, and abnormal electrocardiogram T waves.<br /><br />Based on these results, the researchers concluded that the combination of camrelizumab and famitinib is effective and safe for previously treated patients with advanced NSCLC. However, further validation of these findings is needed.

Asset Subtitle

Ming Gao

Meta Tag

Speaker Ming Gao

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

camrelizumab

famitinib

non-small cell lung cancer

advanced NSCLC

EGFR targeted therapy

chemotherapy

immune checkpoint inhibitor therapy

objective response rate

disease control rate

adverse events